Ikena Oncology

Ikena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding what drives their disease. Ikena leverages core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation product pipeline across distinct molecular targets and biologic pathways that address a broad range of cancers. Ikena went public in March 2021 (NASDAQ: IKNA).

Headquarters Boston, MA
Website www.ikenaoncology.com
Pipeline Clinical
Twitter @IkenaOncology
Partner Bristol-Myers Squibb